Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 7/20 | 0.39 |
| ▸ | GABRP | O00591 | 2/20 | 0.37 |
| ▸ | GABRD | O14764 | 2/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.37 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.37 |
| ▸ | GABRE | P78334 | 2/20 | 0.37 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.37 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.37 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.37 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23620719 | 1.00 | HCAR2 (0.39) | HCAR2GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL6059983 | 0.77 | — | — | |
| SCHEMBL6059987 | 0.77 | — | — | |
| SCHEMBL1323596 | 0.74 | HCAR2 (0.39) | HCAR2 | |
| SCHEMBL1832224 | 0.72 | HCAR2 (0.63) | HCAR2GABRPGABRDGABRA1GABRB1 | |
| Fumaric Acid SCHEMBL7565352 | 0.72 | HCAR2 (0.63) | HCAR2GABRPGABRDGABRA1GABRB1 | |
| Fumaric Acid SCHEMBL7565361 | 0.72 | HCAR2 (0.63) | HCAR2GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL1579344 | 0.72 | HCAR2 (0.63) | HCAR2GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL451816 | 0.72 | HCAR2 (0.63) | HCAR2GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL11103116 | 0.72 | HCAR2 (0.34) | HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104231715-B | A kind of mechanical workpieces paint remover and preparation method thereof | Jurong Jinhou Machinery Research Institute Co., Ltd. (CN) | 2016-04-06 | — | — | CN | claimed |
| CN-104231715-A | Paint remover for mechanical workpiece and preparation method thereof | JURONG JINGHOU MACHINERY RES INST CO LTD | 2014-12-24 | — | — | CN | claimed |
| EP-2686321-B1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL MYERS SQUIBB CO (US) | 2016-11-16 | — | — | EP | disclosed |
| EP-2685981-B1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL MYERS SQUIBB CO (US) | 2016-08-24 | — | — | EP | disclosed |
| CN-104231715-B | A kind of mechanical workpieces paint remover and preparation method thereof | Jurong Jinhou Machinery Research Institute Co., Ltd. (CN) | 2016-04-06 | — | — | CN | disclosed |
| CN-104231715-B | A kind of mechanical workpieces paint remover and preparation method thereof | Jurong Jinhou Machinery Research Institute Co., Ltd. (CN) | 2016-04-06 | — | — | CN | disclosed |
| US-8987268-B2 | Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-24 | — | — | US | disclosed |
| US-8921368-B2 | Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-30 | — | — | US | disclosed |
| CN-104231715-A | Paint remover for mechanical workpiece and preparation method thereof | JURONG JINGHOU MACHINERY RES INST CO LTD | 2014-12-24 | — | — | CN | disclosed |
| EP-2686321-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | Bristol-Myers Squibb Company (US) | 2014-01-22 | — | — | EP | disclosed |
| EP-2685981-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | Bristol-Myers Squibb Company (US) | 2014-01-22 | — | — | EP | disclosed |
| US-20140011795-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL-MYERS SQUIBB COMPANY | 2014-01-09 | — | — | US | disclosed |
| US-20140011800-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL-MYERS SQUIBB COMPANY | 2014-01-09 | — | — | US | disclosed |
| WO-2012125886-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-20 | — | — | WO | disclosed |
| WO-2012125893-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-20 | — | — | WO | disclosed |
| US-20090148615-A1 | METHOD FOR ATMOSPHERIC PLASMA DEPOSITION OF CONJUGATED POLYMER COATINGS | WIAAMSE INSTELLING VOOR TECHNOLOGISCH ONDERZOEK N.V. (VITO) (BE) | 2009-06-11 | — | — | US | disclosed |
| EP-1954412-A1 | A METHOD FOR ATMOSPHERIC PLASMA DEPOSITION OF CONJUGATED POLYMER COATINGS | VLAAMSE INSTELLING VOOR TECHNOLOGISCH ONDERZOEK (VITO) (BE) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007053916-A1 | A METHOD FOR ATMOSPHERIC PLASMA DEPOSITION OF CONJUGATED POLYMER COATINGS | VLAAMSE INSTELLING VOOR TECHNOLOGISCH ONDERZOEK (VITO) (BE) | 2007-05-18 | — | — | WO | disclosed |
| EP-1785198-A1 | A method for atmospheric plasma deposition of conjugated polymer coatings | Vlaamse Instelling voor Technologisch Onderzoek (BE) | 2007-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011795-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | JAK3, JAK1, JAK2 | HCAR2 2881/4885GABRP 1342/4885GABRD 2733/4885 |
| US-20140011800-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | JAK3, JAK1, JAK2 | HCAR2 2884/4885GABRP 1592/4885GABRD 3131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.